Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Baxter
US Army
Boehringer Ingelheim
Daiichi Sankyo
Merck
Accenture
US Department of Justice
Dow

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,259,186

« Back to Dashboard

Which drugs does patent 7,259,186 protect, and when does it expire?

Patent 7,259,186 protects TRILIPIX and is included in one NDA.

This patent has nineteen patent family members in eleven countries.
Summary for Patent: 7,259,186
Title:Salts of fenofibric acid and pharmaceutical formulations thereof
Abstract:In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients.In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
Inventor(s): Cink; Russell Drew (Grayslake, IL), Paterson, Jr.; Joseph B. (Vernon Hills, IL), Gao; Yi (Vernon Hills, IL), Zhang; Geoff G. Z. (Libertyville, IL), Long; Michelle A. (Libertyville, IL), Morris; John B. (Grayslake, IL), Rosenberg; Joerg (Ellerstadt, DE)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/880,851
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation;

Drugs Protected by US Patent 7,259,186

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,259,186

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 60313359 ➤ Sign Up
European Patent Office 1572190 ➤ Sign Up
European Patent Office 1829541 ➤ Sign Up
European Patent Office 1832285 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Moodys
Harvard Business School
Merck
QuintilesIMS
Medtronic
Federal Trade Commission
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.